Overall, these results suggest that SLC26A9 may interact with β-catenin to jointly activate the Wnt/β-catenin signaling pathway and initiate the transcription of downstream target genes, leading to the development and progression of CRC. The gene discussed is SLC26A9; the disease is colorectal carcinoma.